Applied DNA Sciences Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de Applied DNA Sciences disminuyan a un ritmo anual de 51.9%, mientras que sus ingresos anuales crecerán a un ritmo de 37.5% por año. Se espera que el BPA crezca en un 91.5% al año.

Información clave

-51.9%

Tasa de crecimiento de los beneficios

91.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	18.4%
Tasa de crecimiento de los ingresos	37.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	22 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Dec 20

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Aug 17

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Aug 09

Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test

Aug 02

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:APDN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2025	5	-13	N/A	N/A	2
9/30/2024	4	-7	N/A	N/A	2
6/30/2024	3	-8	-14	-13	N/A
3/31/2024	6	-13	-12	-11	N/A
12/31/2023	9	-7	-9	-8	N/A
9/30/2023	13	-10	-7	-6	N/A
6/30/2023	16	-7	-7	-7	N/A
3/31/2023	18	-5	-8	-7	N/A
12/31/2022	19	-7	-8	-8	N/A
9/30/2022	18	-8	-9	-9	N/A
6/30/2022	18	-12	-12	-10	N/A
3/31/2022	15	-15	-12	-10	N/A
12/31/2021	12	-14	-15	-13	N/A
9/30/2021	9	-14	-16	-13	N/A
6/30/2021	6	-14	-14	-12	N/A
3/31/2021	5	-14	-16	-13	N/A
12/31/2020	3	-15	-14	-13	N/A
9/30/2020	2	-13	-12	-11	N/A
6/30/2020	3	-10	-10	-10	N/A
3/31/2020	5	-9	-8	-8	N/A
12/31/2019	5	-8	-8	-8	N/A
9/30/2019	5	-9	-7	-7	N/A
6/30/2019	5	-11	-8	-8	N/A
3/31/2019	4	-12	-8	-7	N/A
12/31/2018	4	-12	-6	-6	N/A
9/30/2018	4	-12	-7	-7	N/A
6/30/2018	4	-11	-6	-5	N/A
3/31/2018	5	-11	N/A	-6	N/A
12/31/2017	4	-12	N/A	-8	N/A
9/30/2017	5	-13	N/A	-7	N/A
6/30/2017	5	-12	N/A	-9	N/A
3/31/2017	4	-13	N/A	-9	N/A
12/31/2016	4	-13	N/A	-9	N/A
9/30/2016	4	-12	N/A	-10	N/A
6/30/2016	7	-10	N/A	-9	N/A
3/31/2016	8	-9	N/A	-8	N/A
12/31/2015	9	-7	N/A	-7	N/A
9/30/2015	9	-12	N/A	-7	N/A
6/30/2015	6	-13	N/A	-7	N/A
3/31/2015	4	-14	N/A	-8	N/A
12/31/2014	3	-15	N/A	-9	N/A
9/30/2014	3	-13	N/A	-9	N/A
6/30/2014	3	-15	N/A	-8	N/A
3/31/2014	3	-15	N/A	-8	N/A
12/31/2013	2	-15	N/A	-8	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que APDN siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que APDN siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que APDN siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (37.5% al año) de APDN crezcan más rápidamente que los del mercado US (8.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (37.5% al año) de APDN crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de APDN se prevé que sea elevada dentro de 3 años.

Applied DNA Sciences Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates fall by 20%

Consensus EPS estimates upgraded to US$5.32 loss

Consensus estimates of losses per share improve by 24%

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

Consensus revenue estimates fall by 49%

Consensus revenue estimates decrease by 13%, EPS upgraded

Recent updates

Applied DNA Sciences, Inc. announced that it has received funding

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.499893 million.

New major risk - Market cap size

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc.'s Applied DNA Clinical Labs, LLC Launches Mpox Clade I and Clade II Testing Service

Applied DNA Sciences, Inc. to Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Applied DNA Sciences, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$5.32 loss

Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

New major risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

Consensus estimates of losses per share improve by 24%

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Consensus revenue estimates fall by 49%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

New minor risk - Share price stability

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

Consensus revenue estimates increase by 12%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 20%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to US$7.00

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA climbs 51% after winning large purchase order

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA stock rises 12% on launching monkeypox testing service in New York

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Applied DNA adds 17% as company seeks approval for monkeypox test in New York

Consensus estimates of losses per share improve by 19%

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise